Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals

Carly Helfand Novartis has been working hard to rack up indications for new med Cosentyx before other next-gen psoriasis competitors hit the scene. And now, it's accomplished that ...

Eleven Bio faces cash crunch as lead drug flunks another PhIII

John Carroll FierceBiotech News

Will Glaxo’s peers follow its anti-corruption lead in China?

Carly Helfand GlaxoSmithKline, post-corruption scandal, has been working hard to clean up its act in China, overhauling its sales practices to wipe out bribery–and its general ...

Novartis keeps its CAR-T lead with positive Phase II data

Damian Garde Novartis, leading a pack of companies developing genetically engineered T cells to fight cancer, unveiled more promising data on its Phase II treatment as it wends toward ...

Boehringer Ingelheim picks family member to lead it through tough times

Eric Palmer Boehringer Ingelheim has picked a member of the founding family as CEO for the first time in a quarter of a century to help it through its lean times. The drugmaker announced ...

Biogen gets beaten up as slowing Tecfidera sales lead it to trim forecast

Eric Palmer The speed bump that sales of Biogen's Tecfidera hit earlier this year, slowing its growth, has turned into a big old pothole and it has shaken investors pretty hard ...

Cara Therapeutics scores another positive PhII for lead opioid

John Carroll FierceBiotech News

Viehbacher returns to lead Swiss billionaire’s $2B biotech fund

Alok Saboo FierceBiotech News

AstraZeneca partner Ardelyx dives (again) as lead drug flunks PhII

John Carroll FierceBiotech News

As patent battle brews, Celgene and GSK lead $64M raise for CRISPR Therapeutics

John Carroll The cascade of venture cash into CRISPR-Cas9 startups is continuing with no end in sight, despite a patent brawl brewing over who owns the technology. Today it's CRISPR ...

J&J, Novartis lead pharma companies by market cap

Carly Helfand Which Big Pharma companies have the biggest market caps in the industry? The Motley Fool has a breakdown of the top 10, but we'll give you a hint: The list ...

Tetraphase spikes on a Phase III success for lead antibiotic

John Carroll Shares of Tetraphase Pharmaceuticals spiked 15% Wednesday afternoon after the biotech said its lead antibiotic hit its primary endpoint in a head-to-head Phase III study, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS